Allogeneic hematopoietic stem cell transplantation is associated with improved long-term survival and molecular MRD clearance in KMT2A-altered AML
Patients with high-risk leukemia who achieve molecular clearance after stem-cell transplant show better survival, offering hope that this measure can guide treatment decisions.
This cohort examined molecular residual disease and transplant outcomes in 155 people with high-risk KMT2A-altered acute myeloid leukemia. Molecular negativity predicted better survival, while transplantation was associated with a much higher rate of sustained molecular clearance.
What the study was
- Study design
- Single-center retrospective cohort with multivariable and time-dependent survival analyses
- Population
- Adolescent and adult patients with KMT2A-altered acute myeloid leukemia
- Sample size
- 155
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Annals of medicine
Why it surfaced
The study addresses a high-unmet-need leukemia subtype with clinically actionable residual-disease findings, but its retrospective single-center design limits certainty.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.